Lee Babiss, Ph.D.

Chairman of the Board

Lee Babiss is the Global Head of Lab Services for PPD where he leads a group of approximately 2500 scientists worldwide. Prior to joining PPD, Lee was the Head of Global Research of Roche until June 2009. He was previously Vice President of Preclinical Research and Development at the company. Earlier, Lee was Vice President of Biological Sciences and Genetics at Glaxo. During his tenure with Glaxo, his positions included Group Leader in Cell Biology, and Head of the Department of Molecular Cell Biology. After the merger of Glaxo with Burroughs Wellcome in 1994, Lee became a member of the US Research Senior Management Team, which formulated the company’s US research strategy. Lee earned his PhD in microbiology in 1982 with Dr. Harold S. Ginsberg at Columbia University, and completed a postdoc at the Rockefeller University.

Dr. Stephan Fischer

Cofounder, CEO

Dr. Fischer spent 26 years in R&D at Boehringer-Mannheim/Roche Pharma Research where he focused on the discovery and development of biological based therapeutics. Stephan was a member of the team that developed erythropoietin (NeoRecormon®) and was the scientific and global project leader of the team that developed the thrombolytic reteplase (Retavase®, Rapilysin®) from discovery to launch. Stephan was a member of the global regulatory strategy committee for Biologics and the global task force for biosimilars. As Senior Vice President, Stephan led the Biologics research organization and developed the global strategy for Roche Biologicals with a focus on innovation and new technologies. Stephan received his PhD in Microbiology and conducted his post-doc at the European Molecular Biology Labs.

Dr. Andreas Tschirky


Until 2010, Andreas Tschirky was General Manager of Roche R&D Center in China where he was responsible for operations of Roche’s Global Pharma Research Center in Shanghai, recognized as the first true R&D Drug Discovery Center in China. Andreas’ tenure at Roche began in 1999 and in 2002 he was appointed Head R&D of Roche in China. Before joining Roche, Andreas worked at several hospital pharmacies and public pharmacies in Switzerland. From 1992-1996, he was the ETH Assistant group leader of an interdisciplinary group of scientists (Biochemistry, Immunology, Molecular Biology, Physics and Nanoscience) at the Paul-Scherrer Institute. Afterwards, he became the project leader for set up and operation of New Adler-Pharmacy at Buchs/St.Gall. Andreas holds a Ph.D. in Pharmacy from the University of Basel, conducted a postdoc in research at the University at Nanjing and earned a MBA from CEIBS (China Europe International Business School).